Mayne Nicholas R, Lin Belle K, Darling Alice J, Raman Vignesh, Patel Deven C, Liou Douglas Z, D'Amico Thomas A, Yang Chi-Fu Jeffrey
Department of Surgery, Duke University, Durham, North Carolina.
University of Arizona College of Medicine-Phoenix, Phoenix, Arizona.
Ann Surg. 2020 Dec;272(6):925-929. doi: 10.1097/SLA.0000000000004363.
To evaluate the overall survival of patients with operable stage IA non-small-cell lung cancer (NSCLC) who undergo "early" SBRT (within 0-30 days after diagnosis) versus "delayed" surgery (90-120 days after diagnosis).
During the COVID-19 pandemic, national guidelines have recommended patients with operable stage IA NSCLC to consider delaying surgery by at least 3 months or, alternatively, to undergo SBRT without delay. It is unknown which strategy is associated with better short- and long-term outcomes.
Multivariable Cox proportional hazards modeling and propensity score-matched analysis was used to compare the overall survival of patients with stage IA NSCLC in the National Cancer Data Base from 2004 to 2015 who underwent "early" SBRT (0-30 days after diagnosis) versus that of patients who underwent "delayed" wedge resection (90-120 days after diagnosis).
During the study period, 570 (55%) patients underwent early SBRT and 475 (45%) underwent delayed wedge resection. In multivariable analysis, delayed resection was associated with improved survival [adjusted hazard ratio 0.61; (95% confidence interval (CI): 0.50-0.76)]. Propensity-score matching was used to create 2 groups of 279 patients each who received early SBRT or delayed resection that were well-matched with regard to baseline characteristics. The 5-year survival associated with delayed resection was 53% (95% CI: 45%-61%) which was better than the 5-year survival associated with early SBRT (31% [95% CI: 24%-37%]).
In this national analysis, for patients with stage IA NSCLC, extended delay of surgery was associated with improved survival when compared to early treatment with SBRT.
评估接受“早期”立体定向体部放疗(SBRT,诊断后0至30天内)与“延迟”手术(诊断后90至120天)的可手术IA期非小细胞肺癌(NSCLC)患者的总生存期。
在2019冠状病毒病大流行期间,国家指南建议可手术的IA期NSCLC患者考虑将手术推迟至少3个月,或者立即接受SBRT。目前尚不清楚哪种策略与更好的短期和长期预后相关。
采用多变量Cox比例风险模型和倾向评分匹配分析,比较2004年至2015年国家癌症数据库中接受“早期”SBRT(诊断后0至30天)的IA期NSCLC患者与接受“延迟”楔形切除术(诊断后90至120天)的患者的总生存期。
在研究期间,570例(55%)患者接受了早期SBRT,475例(45%)接受了延迟楔形切除术。在多变量分析中,延迟切除与生存期改善相关[调整后风险比0.61;(95%置信区间(CI):0.50 - 0.76)]。倾向评分匹配用于创建两组,每组279例接受早期SBRT或延迟切除的患者,两组在基线特征方面匹配良好。与延迟切除相关的5年生存率为53%(95%CI:45% - 61%),优于与早期SBRT相关的5年生存率(31%[95%CI:24% - 37%])。
在这项全国性分析中,对于IA期NSCLC患者,与早期SBRT治疗相比,延长手术延迟与生存期改善相关。